Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Baggins, Nickel prices have more than doubles from below < 10k/tonne to above 22k/tonne - so they have become hugely lucrative since NN were the operator. Nickel demand for 2022 onwards is projected to go go through the roof, along with the price.
But then you knew that anyway.
I suspect that this RNS is about getting their house in order ready for the long awaiting sale/s.
Wishfull thinking perhaps - do we know - once the test has been tweaked then do we need a full evaluation of the "new" test/product and do Avacta need to resubmit or amend the documents to gain its CE and HUA status's.
* ... all else is just noise
Disappointing but not the end. TT will need tweaking and new tests verifying once Avacta sort them out. More disappointing is news that the other TT is still a couple of months from completion (end of Q1).
IMO, Those that offloaded first thing did well (I never) those that ride out the storm and/or buy in at the bottom (which I am guessing will be Wed afternoon ish) will do well. All is is just noise.
GLA
GLR, I have done extensive research on both Companies, watched every presentation/interview and read every RNS, so more than happy that I have enough info to make the right trading decisions (for me). There are enough pathetic muppets on those boards that think that sticking the boot into one company will somehow benefit the other without me joining in- not my game thanks.
GLR, I have done extensive research on both Companies, watched every presentation/interview and read every RNS, so more than happy that I have enough info to make the right trading decisions (for me). There are enough pathetic muppets on those boards that think that sticking the boot into one company will somehow benefit the other without me joing in- not my game thanks.
Not sure that you can compare both companies - ODX have have their CD4, Food Intolerance / Glabal Health testing to underpin a lot of their marketcap. I am invested in both, both are still high risk still with potential very high reward, and hopefully both will do very well eventually.
I do agree that Abdx at the minute looks a better bet for a steeper rise on news due to its smaller MC and simpler model, news on TT with the Avacta test being completed will get this moving, but it will take orders to really get the boosters on.
Fingers crossed that the wait isn't too long for both companies.
Very good chance that this is still a closed period for director dealings - not so much due to Val201 but because of the NDAs in place with the Japanese Pharma and the University. Also any iminent update on CovidCM201 or 401 that we do not know about would prevent any directors from buying as well as another compound evaluation announcement that may be close.
I believe that there is a good chance that we will see the signature for Val201 shortly - TheoremRx will want/need the funding wrapped up long before they start the trials and although their Scientist's will be talking to potential hospitals with Suzy, nothing can be agreed until they have the funds in place and have signed the agreement.
Those wanting directors dealing are likely looking for short term trading opportunities, and good luck to them, but if you do your research the real value will be those holding and letting the BoD do their job, not pampering to Retail investors by buying token amounts of shares.
Ignore the Fools on here - Theorem only, in my opinion, will be looking to raise 15-20$mill - relatively small xhange across the pond.
They could always raise another $60mil, build a stake and try to take Val out in it entirity. :-) - it would save them a lot of dosh in the longer term.
Iceman, interview today - are you sure?. Those things usually take a little bit of time to set up although I know that the Company will be keen to put some meat on the bone for those that are "prepared to listen".
I have found Suzy to be always extremely professional and always replied to emails in a very timely manner, including this morning. If anyone has any real concerns then I suggest that they may want to get in touch with the Company directly - the Company obviously can't and won't divulge any info not in the public domain, nor would I expect them to, but still a worthwhile exercise - (just don't post any replies on this or any other public forum, it is unprofessional and will only erode trust between the Company and PI's).
I do look forward to an interview in the next day or so or when they get a slot.
GLA, those that are prepared to listen and have done their research will realise the importance of this news and that it was the next step in the process and needed to happen.
D
It doesn't help that many muppets on here cannot read an RNS - this RNS is formalising the Service Agreement tjat was alluded to on the 02nd Nov RNS. This RNS states that the Company also believes everything is still on track and moving forward with TheoremRx with the sub licence deal - subject to TheoremRx completing their own fund raise.
The reason there is no mention of the upfront payments on the RNS (as some have highlighted) is because that is part of the licensing deal, not this Service agreement. So despite what some wrote earlier - the "deal" for licensing Val201 hasn't been amended and the upfront payments will still be paid to Val.
This RNS says that there is a slight delay in TheoremRx signing but all is still on track with the Licencing deal, it also says that other areas are progressing well and that T'Rx have now formally agreed to pay for Val advisory services going forward.
Pretty sure Suzy will confirm this in an interview shortly.
MD, "by Friday", maybe - I am sure that Suzy will be on the blower to Ken Sorensen asking for an update today. I would however prefer to see the SP back into the 40's before news - that way the II's will pay more and any of the bed-wetters on here and those predicting a drop this week (to buy in cheaper) will pay substantially more on any positive RNS.
What do we have - in my opinion we have real short, medium and long term triggers that should see the SP potentially a lot higher than where it is now - bear in mind that a few weeks ago the SP touched mid 60"s based on a letter of intent to sub license Val 201.
Short term (days or weeks at most) we could/should recieve news that the deal with TheoremRx has been signed and first payments recieved - this will basically not only fund all operating costs, but also fund the current pipeline and any current and future evaluations.
Short to medium term - hopefully the Japanese Farma will take Val301 forward, if not then another commercial deal may be announced.
Val 401 (lung and pancreatic cancer) is ready to go and any tie-in with med Biothech/SPV's will be huge news.
Medium term (Q2/3) should see the triple-ne' breathing cancer compound eval complete and moved to pre clinical trials - this in my opinion is one where Big Pharma could come in for pre-phase 1 (early 2023 potentially) which would be transformational to the Company.
II's will arrive when Val201 licence is signed and income generation guaranteed from TheoremRx.
Fingers crossed for news soon.
DK and others - you will get your RNS when things are signed or there is a known reason for any delay to the licensing agreement- any other RNS would be as amateur as those posting on here asking for one.
Not disappointed at all, not even a tad. Val have done everything their end, just awaiting Uncle Sam to do his.
No change to the direction - expectation is year end, and delays to this will be RNS'd. So if TheoremRx ask for another month or the licence needs further tweaking that causes any delay then I expect an RNS - otherwise nothing has changed and we will hear news when the deal is signed. So unless their is substantial delays or the licence agreement isn't going through then I see absolutely no reason for any RNS until we see this finalised. Year end was always ambitious, given Thanksgiving and Christmas - I don't think it will drag too far into Q1/22 in fact early Jan will do just fine. News today would have been lost over the new year period, releasing the RNS when the markets open Jan will have the greatest impact on the SP, good or bad.